Speaker Lecture Titles

PARTIAL LIST OF CONFIRMED SPEAKERS

Surname

First name

Country

Title

Babic Tomislav Austria CHALLENGES OF DRUG DEVELOPMENT IN L-DOPA NAÏVE SUBJECTS WITH DIAGNOSIS OF EARLY PARKINSON’S DISEASE
Becker Robert USA WILL INHIBITING NEURONAL CELL DEATH PROVIDE BENEFITS TO ALZHEIMER’S DISEASE PATIENTS?
Blennow Kaj Sweden MONITORING BRAIN AMYLOIDOSIS, TAU PATHOLOGY AND NEURODEGENERATION BY PLASMA MEASUREMENTS, PROGRESS TOWARDS RELIABLE AND SENSITIVE TESTS.
Bu Goujun USA TREM2 AND ITS AD RISK VARIANTS IN MICROGLIAL FUNCTIONS
Buee Luc France FROM GENE TRANSFER TO ANTIBODY: WHICH DEVELOPMENT FOR TAU IMMUNOTHERAPY
Cattaneo Annamaria Italy ROLE OF THE GUT MICROBIOTA, INFLAMMATION AND THEIR INTERPLAY IN THE PATHOGENESIS AND PROGRESSION OF ALZHEIMER DISEASE
Checler Frédéric France BETA-CTF: A KEY PLAYER LINKED TO AUTOPHAGIC/LYSOSOMAL DYSFUNCTION
Chiba-Falek Ornit USA NEXT-GENERATION GENE THERAPY FOR PRECISION MEDICINE IN AGE-RELATED NEURODEGENERATIVE DISEASES: TARGETED EPIGENOME EDITING TO REVERSE SNCA DYSREGULATION IN PD
Cleveland Don USA GENERATING NEW NEURONS IN THE ADULT MAMMALIAN NERVOUS SYSTEM: CONVERTING ASTROCYTES INTO NEURONS PRODUCES THERAPEUTIC REVERSAL OF CHEMICALLY INDUCED PARKINSON DISEASE
Cudkowics Merit USA ALS PLATFORM TRIAL INITIATIVE: ACCELERATING THERAPY DEVELOPMENT
Cuello Claudio Canada IS THE NGF METABOLIC PATHWAY A PROMISING CANDIDATE FOR AD BIOMARKERS AND THERAPY ?
Engelborghs Sebastiaan Belgium TBA
Ferretti Maria Teresa Switzerland SEX AND GENDER DIFFERENCES IN ALZHEIMER’S DISEASE – GATEWAY TO PRECISION MEDICINE
Frisoni Giovanni Switzerland FECAL TRANSPLANTATION TO PREVENT ALZHEIMER’S DISEASE: PRECLINICAL STUDIES
Froelich Luz Germany CONCLUSIONS FROM THE NEGATIVE PHASE III TRIALS – HOW TO ADAPT DRUG DEVELOPMENT IN AD
Galvin James USA CAN DEMENTIA BE PREVENTED: NEW LESSONS LEARNED AND APPLIED IN RESEARCH AND CLINICAL PRACTICE
Gerwert Klaus Germany PRECLINICAL STRUCTURE BASED BLOOD TEST IDENTIFIES HIGH RISK PARTICIPANTS FOR CLINICAL TRIALS
Geula Changiz USA TBA
Giacobini Ezio Switzerland USING CHOLINESTERASE INHIBITORS TO TREAT ALZHEIMER PATIENTS AT DIFFERENT STAGES OF THE DISEASE. WHAT WE HAVE LEARNED IN 25Y EXPERIENCE!
Gold Gabriel Switzerland MICROINFARCTS AND MICROBLEEDS : AGE OR DEMENTIA RELATED ?
Growdon John USA ANTI-ABETA AND ANTI-TAU TREATMENTS WILL BENEFIT PARKINSON DISEASE
Hannson Oskar Sweden FLUID AND PET IMAGING MARKERS OF TAU PATHOLOGY IN THE DIAGNOSTIC WORK-UP OF DEMENTIA DISORDERS
Hartmann Tobias Germany LONG-TERM EFFECTS OF MULTI NUTRIENT INTERVENTION IN THE PRODROMAL AD LIPIDIDIET CLINICAL TRIAL
Heneka Michael Germany MICROGLIAL PATHOLOGY DRIVES NEURONAL DYSFUNCTION AND DEGENERATION IN ALZHEIMER’S DISEASE
Hort Jakub Czech Republic CHALLENGES OF DRUG DEVELOPMENT: SUBJECTS IN CLINICAL TRIALS AND REAL PATIENTS AT MEMORY CLINIC
Hyman Bradley USA CONTRIBUTIONS OF NEURONAL LOSS, AB, TAU, AND VASCULAR DYSFUNCTION IN PROGRESSION OF ALZHEIMER’S DISEASE
Iwatsubo Takeshi Japan TOWARD VERY EARLY TREATMENT OF ALZHEIMER’S DISEASE
Jagust William USA TAU IMAGING, MEMORY, AND THE BEGINNING OF ALZHEIMER’S DISEASE
Jeon Beomsoek Korea PERIPHERAL TISSUE BIOMARKERS IN PD AND THEIR IMPLICATION
Kantarci Kejal USA IMAGING BIOMARKERKERS IN DLB: HOW EARLY CAN THEY BE DETECTED?
Kulisevsky Jamie Spain HALLUCINATIONS IN PD: CLINICAL AND NEUROIMAGING CORRELATES
Marek Ken USA DEVELOPING A PD PRODROMAL BIOMARKER SIGNATURE
Michaelson Daniel Israel APOE4 TARGETED THERAPY OF ALZHEIMER’S DISEASE BASED ON ACTIVATION OF THE LIPIDATING TRANSPORTER  ABCA1
Molinuevo José Luis Spain THE ROLE OF PLASMA BIOMARKERS IN FUTURE CLINICAL CARE
Morris John USA “WHAT WE CAN LEARN FROM FAMILIAL AD?”.
Nordberg Agneta Sweden TAU PET TRACERS  , HOW SPECIFIC FOR AD AND  NON –AD TAUOPATHIES- STILL A DILEMMA?
Outeiro Tiago Germany THE MOLECULAR BASIS FOR THE SPREADING OF ALPHA-SYNUCLEIN: THERAPEUTIC TARGETS FOR INTERVENTION
Poewe Werner Austria NOVEL APPROACHES TO DISEASE-MODIFICATION IN PD
Rabinovici Gil USA PET IMAGING IN NON-AD TAUOPATHIES: PROGRESS AND CHALLENGES
Rascol Oliver France CURRENT AND FUTURE APPROACHES OF THE PHARMACOLOGICAL MANAGEMENT OF OFF EPISODES IN PARKINSON DISEASE
Rektorova Irena Czech Republic COMBINATORIAL BIOMARKER ANALYSIS IN LEWY BODY DISEASES
Schapira Tony United Kingdom PROGRESS IN THERAPEUTIC STRATEGIES FOR DISEASE MODIFICATION IN PARKINSON DISEASE
Scheltens Philip The Netherlands NEW BLOOD MARKERS FOR ALZHEIMER’S: WHERE DO WE STAND?
Schlossmacher Michael Canada LRRK2 AND A-SYNUCLEIN FUNCTIONS IN INNATE IMMUNITY: LESSONS FOR TARGETED THERAPY IN PARKINSON’S
Schmidt Reinhold Austria MRI-DETECTED IRON DEPOSITION IN NORMAL AGING AND DEMENTIA
Schmitz Taylor United Kingdom TBA
Sisodia Sangram USA REGULATION OF AD-TYPE NEUROPATHOLOGICAL HALLMARKS BY THE GUT MICROBIOME
Solomon Beka Israel MOBILIZATION OF ENDOGENOUS MICROGLIA-LIKE HEMATOPOIETIC STEM CELLS AS A THERAPEUTIC STRATEGY FOR TREATMENT OF ALZHEIMER’S DISEASE WITH NEW DATA
Soreq Hermona Israel NEAT1 ELEVATION UNDER OXIDATIVE STRESS CONFERS LRRK2-MEDIATED PROTECTION OF PARKINSON’S SUBSTANTIA NIGRA NEURONS
Stocchi Fabrizio Italy TREATMENT OF UNEXPECTED OFF EPISODES IN PARKINSON’S DISEASE
Tanzi Rudy USA THE ROLE OF MICROBES AND INNATE IMMUNE GENES  IN ALZHEIMER’S DISEASE
Vassar Robert USA TBA
Vemuri Prashanthi USA IMAGING MARKERS OF RESILIENCE AND RESERVE IN ALZHEIMER’S DISEASE
Villemagne Victor Australia TAU IMAGING IN AD AND NON-AD TAUOPATHIES
Weiner Michael USA IMAGING AND BIOFLUID BIOMARKERS TO OPTIMIZE AD CLINICAL TRIALS: ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) AND BRAIN HEALTH REGISTRY
Weiner Howard USA TBA
Wong Philip USA FUNCTIONAL VALIDATION OF TDP-43 SPLICING REPRESSION AS A THERAPEUTIC TARGET FOR ALS-FTD
Yamada Masahito Japan TRANSMISSION OF ABETA PATHOLOGY LEADING TO EARLY-ONSET CEREBRAL AMYLOID ANGIOPATHY IN HUMANS
Zhou Jiawei China ROLE OF NG2 GLIA IN THE REGULATION OF NEUROINFLAMMATION: IMPLICATION IN PARKINSON’S DISEASE.